IGI Labs, Inc. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Virtual Booth

Contact Supplier

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

1 News #PharmaBuzz

media
1 News #PharmaBuzz

FINISHED DOSAGE FORMULATIONS

55 FDF Dossiers, 55 FDA Orange Book

55 FDF Dossiers
55 FDA Orange Book

INSPECTIONS & REGISTRATIONS

6 FDA, 1 GDUFA

inspections
6 FDA
1 GDUFA

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IGI Laboratories, Inc. is a fast-growing developer, manufacturer, and marketer of topical formulations. Our goal is to become a leader in the generic topical pharmaceutical market. Under our IGI label, we sell generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. We also provide development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic markets. IGI Laboratories is conveniently located in southern New Jersey. Our 25,000 square foot facility offers full turnkey operations for topical products. Our plant is designed to provide cost-effectiveness, reduced cycle time, flexibility, and quality. We offer a fully-integrated facility, complete with on-site development laboratories, bulk manufacturing, analytical and microbiological testing laboratories, and high-speed filling operations. IGI’s facilities are cGMP compliant and have been inspected by the US FDA. The company’s strategic plan is to continue to build upon this foundation by expanding its generic prescription pharmaceutical business. Strategic Initiatives Our strategy is based on three initiatives: • Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in our own label in topical dosage forms • Increasing our current contract manufacturing and development business • Creating unique opportunities through the acquisition of additional intellectual property, and the expansion of the use of our existing intellectual property, including our licensed Novasome® technology